



# Proteomics International

LABORATORIES LTD

ASX/Media Release

10 October 2017

ASX code: PIQ

## Proteomics International receives nearly \$800,000 in R&D tax incentive

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a leader in predictive diagnostics and analytical services, is pleased to announce that its balance sheet has been boosted by the receipt of nearly \$800,000 in research and development tax incentive for the 2016-17 financial year.

Proteomics International's business model sees the company pursue pioneering research with blue-sky potential in next generation diagnostic tests and drug discovery using revenue generated from providing sophisticated analytical services.

In 2016-17, Proteomics International spent \$1.82 million on R&D, making the company eligible for an Australian Government rebate of \$786,225.

Proteomics International continues to invest heavily in the commercialisation of its world-leading diabetic kidney disease test, PromarkerD, its biomarker discovery program, and developing new fee-for-service methods.

The Federal R&D tax incentive encourages companies engaging in beneficial research to Australia by providing a cash rebate of 43.5% for qualifying activities.

ENDS

### For further information please contact:

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)  
[www.proteomicsinternational.com](http://www.proteomicsinternational.com)

Paul Hart [Investor Relations]  
Director  
Canary Capital  
T: +61 421 051 474  
E: [phart@canarycapital.com.au](mailto:phart@canarycapital.com.au)

Susan Fitzpatrick-Napier [Media Contact]  
Digital Mantra Group  
T: +61 2 8218 2144  
E: [team@dmgpr.com](mailto:team@dmgpr.com)

### About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)

pharmaceutical industry because of their intimate role in biological systems. Proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia. The company's business model harnesses its proprietary technology platform to work across three integrated areas, each massive growth markets:

**1. Diagnostics:** Biomarkers of disease and personalised medicine - focus on diabetic kidney disease.

By 2020 the biomarkers market is estimated to double in size to \$45.6 billion, and the personalised medicine market is forecast to be worth over \$149 billion.

**2. Analytical services:** Specialist contract research – focus on biosimilars QC and pharmacokinetic testing for clinical trials.

The global biosimilars market is expected to reach \$10.5 billion by 2022, having surpassed \$3.3 billion in 2016 as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.

**3. Drug discovery:** Therapeutic peptide drug discovery - focus on painkillers and antibiotics.

The global peptide therapeutics market is currently estimated to be worth \$18 billion with a chronic need to find new drugs to combat bacterial infections.